Biologics & mAbs (Monoclonal Antibodies)
From cell line development to commercial scale-up - Aventiq Bio provides independent technical governance for mAbs, recombinant proteins, and biosimilars in India’s leading biopharma hubs
Navigate the Biologics Frontier with Process Certainty
Biologics & mAbs (Monoclonal Antibodies)
Monoclonal antibodies and biologics represent precision medicine's cornerstone, but outsourcing introduces hidden vulnerabilities: cell line drift, comparability failures, immunogenicity risks from impurities, and protracted biosimilar approvals
Aventiq Bio serves as your technical guardian - delivering unbiased oversight, process rigor, and regulatory foresight to harness India's maturing mammalian ecosystem with global confidence and 40–60% cost advantages
-
Cell Line Drift & Productivity Loss
High-titer clones failing to maintain stability or quality at commercial 2000L scale
-
Analytical Comparability Nightmares
Subtle PTM differences or HCP impurities failing FDA/EMA biosimilarity bridges
-
Tech Transfer Gaps
Excellent bioreactor runs undermined by inadequate analytical characterization (mass spec, bioassays) for global filings
-
Immunogenicity Risks
Residual HCPs/DNA from lower-cost facilities triggering adverse responses in trials
-
Biosimilar Regulatory Hurdles
Proving "highly similar" across structure, function, and clinical performance under stringent guidelines
India's Rising Biologics & Biosimilar Leadership
Precision Oversight Across the Biologics & Biosimilar Lifecycle
We deliver phase-specific technical governance - ensuring robust, scalable, and approval-ready processes for mAbs and biosimilars
Upstream & Cell Line Development (CLD) Advisory
Ensure your product is built on a stable, high-titer foundation – Selection and vetting of CLD partners – Oversight of vector design, transfection, clone selection, and productivity optimization
Downstream Process (DSP) & Purification Oversight
Maximize recovery without compromising purity or viral safety – Strategy for chromatography (Protein A, IEX, HIC) and UF/DF optimization – Viral clearance study design and oversight
Analytical Characterization & Comparability
The data-driven bridge to global biosimilar approval – Oversight of physicochemical and biological activity assays – Forced degradation, stability (ICH Q5C), and higher-order structure analysis
Facility & GMP Readiness Audits
Securing the sterile core of your bioprocess – Independent audits of single-use/stainless facilities and EM programs – Media fill and aseptic process simulation oversight
Therapeutic Peptides Support
While our primary focus is monoclonal antibodies and biosimilars, we provide targeted advisory for therapeutic peptides - often overlapping with biologics platforms in expression and purification
-
Contact us if your program involves therapeutic peptides - we integrate this expertise with our core biologics capabilities.
Why Aventiq Bio – Your Biologics Guardian
Proprietary database of proven mammalian platforms and biosimilar-experienced facilities
Deep analytical and comparability expertise (multiple successful global dossiers)
On-ground bioprocess scientists for real-time intervention
True independence - unbiased recommendations for optimal outcomes
Track record in mAbs, recombinant proteins, and biosimilar acceleration
All Aventiq Bio biologics oversight adheres to ICH Q5/Q6, FDA/EMA biosimilarity guidelines, and ALCOA+ principles - delivering seamless global acceptance